Inhibition of G1 to S Phase Progression by a Novel Zinc Finger Protein P58TFL at P-bodies

Kentaro Minagawa, Yoshio Katayama, Shinichiro Nishikawa, Katsuya Yamamoto, Akiko Sada, Atsuo Okamura, Manabu Shimoyama, and Toshimitsu Matsui

Hematology/Oncology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

Abstract

We recently reported the translocation of the immunoglobulin (lg) light chain k locus gene with a possible tumor suppressor gene, TFL, in transformed follicular lymphoma. However, the functional significance in cell transformation remains to be elucidated. Here, we first identified two gene products, P58TFL and P36TFL, derived by alternative splicing. The expression was prominent in normal human lymphocytes but defective in some leukemia/lymphoma cell lines. Overexpression of either protein in a mouse pro-B cell line, Ba/F3, and a human leukemia cell line, Jurkat, inhibited G1 to S phase progression through suppression of retinoblastoma protein (Rb) phosphorylation. The dominant gene product, P58TFL, colocalized with mRNA-processing body markers, eukaryotic translation initiation factor 2C and DCP1 decapping-enzyme homolog A, but not with a stress granule maker, T-cell intracellular antigen 1, in the cytoplasm. Taken together with the unique CCCH-type zinc finger motif, the present study suggests that P58TFL could play an important role in the regulation of cell growth through posttranscriptional modification of cell cycle regulators, at least partially, upstream of Rb. (Mol Cancer Res 2009;7(6):880–9)

Introduction

Cytogenetic abnormalities contribute not only to tumor initiation but also to tumor progression for many types of malignancies derived from hematopoietic, mesenchymal, and epithelial tissues (1-5). Neither the BCR/ABL fusion protein derived from Philadelphia chromosomes in chronic myeloid leukemia (6, 7) nor BCL-2 overexpression due to the BCL-2 translocation to the immunoglobulin loci in B-cell lymphomas is capable of triggering cell transformation by itself (8, 9). Another genetic mutation is required for full transformation.

For example, additional cytogenetic mutations are well documented in chronic myelogenous leukemia blast crisis. Similarly, in the transformation of BCL-2-positive follicular lymphoma into aggressive lymphoma, many cytogenetic abnormalities have been reported (10). Among them, loss of regions in the long arm of chromosome 6 (6q), which is frequently observed not only in hematologic but also in epithelial malignancies (11, 12), has been reported to be associated with poor prognosis (13, 14). These findings suggest the existence of an as yet uncharacterized tumor suppressor gene on 6q21-25.

To pave the way for the identification of tumor suppressor gene candidates, microarrays such as array based-comparative genomic hybridization, which can visualize gene amplification and/or other defects in cancer, have been used by several groups around the world. Indeed, loss of 6q21-q27 was reported to be frequent in B-cell lymphoma (15, 16).

Alternatively, a rare cytogenetic translocation sometimes reveals a novel oncogene or cryptic mutation important for tumorigenesis or leukemogenesis. For example, the tumor suppressor gene HACE1 was first identified from a t(6;15) translocation in a Wilms’ tumor sample. Thereafter, HACE1 was shown to be involved in multiple cancers (17, 18). The universal cryptic defect of the α-type platelet-derived growth factor receptor gene (αPDGFR) in chronic eosinophilic leukemia was also first identified from a rare case with t(1;4) (q44;q12) (ref. 19). Thereafter, the genetic change established a new clinical entity defined in the updated WHO classification (20).

Recently, we identified a possible tumor suppressor gene at the break points of the t(2;6)(p12;q25) translocation in a transformed follicular lymphoma, designated TFL (21, 22). The break point was located at the putative second intron of ZC3H12D, an orphan gene previously defined by the human genome project (GenBank accession no. NM 207360). The gene presumably encodes a single “Cys-x8-Cys-x5-Cys-x3-His” (CCCH)-type zinc finger protein, and was recently reported to be a novel tumor suppressor gene candidate. Its loss of heterozygosity was found in sporadic lung cancer, and a single-nucleotide polymorphism at codon 106 was shown to affect tumor growth (23).

However, the TFL gene structure, its gene products, or their physiologic function has not yet been determined. Reports of the exon organization of ZC3H12D transcripts have been frequently rewritten on the web site of National Center for Biotechnology Information (NCBI). To clarify the functional significance of this tumor suppressor gene candidate in cell transformation, we investigated the TFL gene products and their expression profiles and biological function.
Results

Identification of Two Alternatively Spliced Transcripts

At the beginning of our cDNA cloning, two independent genes, ZC3H12D and “an orphan gene encoding FLJ00361 protein (accession #AK090441),” were listed at the NCBI database. RNA blot analysis using a DNA fragment of the TFL gene cloned from a genomic library constructed from a patient’s lymph node with t(2;6)(p12;q25) (ref. 22) and a 5.5-kb cDNA clone, FLJ00361, provided by KAZUSA DNA Research Institute (Tsukuba, Japan), supported the possibility that FLJ00361 5.5-kb cDNA lacking a large part of the ORF in TFL1 or TFL2 has a long intron 6 sequence.

Expression Profiles in Normal Tissues and Leukemic Cell Lines

We first examined mRNA expression in human blood to gain insight about the functional significance of TFL in malignant lymphoma (Fig. 2A). The 5-kb TFL transcript was abundantly expressed in human lymph nodes as well as in normal peripheral T and B lymphocytes. In contrast, human bone marrow expressed less of this transcript. Human B-cell (Daudi and Nalm6) and some myeloid leukemia/lymphoma cell lines (THP-1) expressed TFL as well as did lymph nodes. However, it was less abundant in another myeloid leukemic cell line, HL60. In contrast, mRNA expression in T-cell leukemia/lymphoma cell lines (Jurkat, Molt14, and CCRF/CEM) was undetectable. A smaller transcript (∼3.2 kb) was also seen in THP-1 and Daudi cells, which was compatible in size with our cDNA clone TFL1.

We next examined mRNA expression in other normal tissues. The 5-kb transcript was prominently expressed in mouse lymphoid organs, spleen, and thymus (Fig. 2B, left). The mRNA was also detectable in lung, stomach, and kidney, whereas it was undetectable in brain, heart, liver, and muscle. Mouse TFL was also expressed in both splenic T and B lymphocytes (Fig. 2B, right). Although the transcript was not detectable in mouse bone marrow, a faint expression was seen not only in the mouse pro-B-cell line Ba/F3 but also in the myeloid progenitor cell line 32D.

These results indicate that TFL is predominantly expressed in normal lymphoid tissues and that some lymphoid malignancies lack expression.

Identification of the Major Protein Expressed in Human Blood

We next confirmed the expression of TFL-encoded protein by developing polyclonal antisera against recombinant protein derived from a TFL2 cDNA expression vector. As shown in Fig. 1, the first 298 amino acids encoded by TFL1 are identical to those of TFL2. Thus, the antisera could recognize a 58-kDa protein, P58TFL, in Ba/F3 cells transfected with a TFL1 expression vector (Fig. 3A). P58TFL was preferentially expressed in human peripheral mononuclear cells (MNC) but not in polymorphonuclear cells (PMN). The expression pattern in human blood occurs in the ORF of TFL2, resulting in a stop codon TAG by alternative splicing (Fig. 1B). Consequently, a frame shift is introduced, which predicts a 249-bp 5′ UTR (Fig. 1A). The 2.9-kb TFL2 cDNA had the identical exons 1 to 5 and exon 7 of TFL1, whereas it was undetectable in another myeloid leukemic cell line, HL60. In contrast, mRNA expression in T-cell leukemia/lymphoma cell lines (Jurkat, Molt14, and CCRF/CEM) was undetectable. A smaller transcript (∼3.2 kb) was also seen in THP-1 and Daudi cells, which was compatible in size with our cDNA clone TFL1.

Expression Profiles in Normal Tissues and Leukemic Cell Lines

We first examined mRNA expression in human blood to gain insight about the functional significance of TFL in malignant lymphoma (Fig. 2A). The 5-kb TFL transcript was abundantly expressed in human lymph nodes as well as in normal peripheral T and B lymphocytes. In contrast, human bone marrow expressed less of this transcript. Human B-cell (Daudi and Nalm6) and some myeloid leukemia/lymphoma cell lines (THP-1) expressed TFL as well as did lymph nodes. However, it was less abundant in another myeloid leukemic cell line, HL60. In contrast, mRNA expression in T-cell leukemia/lymphoma cell lines (Jurkat, Molt14, and CCRF/CEM) was undetectable. A smaller transcript (∼3.2 kb) was also seen in THP-1 and Daudi cells, which was compatible in size with our cDNA clone TFL1.

We next examined mRNA expression in other normal tissues. The 5-kb transcript was prominently expressed in mouse lymphoid organs, spleen, and thymus (Fig. 2B, left). The mRNA was also detectable in lung, stomach, and kidney, whereas it was undetectable in brain, heart, liver, and muscle. Mouse TFL was also expressed in both splenic T and B lymphocytes (Fig. 2B, right). Although the transcript was not detectable in mouse bone marrow, a faint expression was seen not only in the mouse pro-B-cell line Ba/F3 but also in the myeloid progenitor cell line 32D.

These results indicate that TFL is predominantly expressed in normal lymphoid tissues and that some lymphoid malignancies lack expression.

Identification of the Major Protein Expressed in Human Blood

We next confirmed the expression of TFL-encoded protein by developing polyclonal antisera against recombinant protein derived from a TFL2 cDNA expression vector. As shown in Fig. 1, the first 298 amino acids encoded by TFL1 are identical to those of TFL2. Thus, the antisera could recognize a 58-kDa protein, P58TFL, in Ba/F3 cells transfected with a TFL1 expression vector (Fig. 3A). P58TFL was preferentially expressed in human peripheral mononuclear cells (MNC) but not in polymorphonuclear cells (PMN). The expression pattern in human blood occurs in the ORF of TFL2, resulting in a stop codon TAG by alternative splicing (Fig. 1B). Consequently, a frame shift is introduced, which predicts a 249-bp 5′ UTR (Fig. 1A). The 2.9-kb TFL2 cDNA had the identical exons 1 to 5 and exon 7 of TFL1, whereas it was undetectable in another myeloid leukemic cell line, HL60. In contrast, mRNA expression in T-cell leukemia/lymphoma cell lines (Jurkat, Molt14, and CCRF/CEM) was undetectable. A smaller transcript (∼3.2 kb) was also seen in THP-1 and Daudi cells, which was compatible in size with our cDNA clone TFL1.

We next examined mRNA expression in other normal tissues. The 5-kb transcript was prominently expressed in mouse lymphoid organs, spleen, and thymus (Fig. 2B, left). The mRNA was also detectable in lung, stomach, and kidney, whereas it was undetectable in brain, heart, liver, and muscle. Mouse TFL was also expressed in both splenic T and B lymphocytes (Fig. 2B, right). Although the transcript was not detectable in mouse bone marrow, a faint expression was seen not only in the mouse pro-B-cell line Ba/F3 but also in the myeloid progenitor cell line 32D.

These results indicate that TFL is predominantly expressed in normal lymphoid tissues and that some lymphoid malignancies lack expression.
hematopoietic cell lines was completely consistent with the results of RNA blot analyses (Figs. 2A and 3A).

To further confirm the specificity of the antisera, we performed immunoblot analysis using immunoprecipitates. The P58TFL was specifically immunoprecipitated, but a nonspecific signal (indicated by a star just above P58TFL) that was detected in cell lysates was absent (Fig. 3). With regard to protein encoded by TFL2, the antisera could recognize recombinant P36TFL expressed in a mammalian cell line (Fig. 3B). Both molecular weights (MW) observed experimentally by SDS-PAGE analysis were compatible with those predicted from their primary structures. P36TFL seems to be similar to a provisionally named p34, although there is a four-amino-acid difference from codon 298 to codon 301 (P34, Pro-Val-Leu-Pro; P36TFL, Leu-Gly-Val-Arg, respectively) by possible alternative splicing of exons 6a and 6b (23). However, the endogenous P36\textsuperscript{TFL} was

FIGURE 2. Tissue-specific mRNA expression. A, RNA blots of normal human lymph nodes (LN), peripheral blood (PB) T and B lymphocytes, and bone marrow (BM; left) and human leukemia/lymphoma cell lines (HL-60, THP-1, Jurkat, Molt-14, CCRF/CEM, Daudi, and Nalm6) were probed with a human cDNA fragment covering the common ORF of TFL1 and TFL2. The positions of 28S and 18S rRNAs are shown. Ethidium bromide (EtBr) staining of 28S rRNA is also shown at the bottom of the blots. B, RNA blots of normal mouse tissues (left) and mouse bone marrow, splenic T and B lymphocytes, IL-3-dependent pro-B cell line, Ba/F3, and myeloid progenitor cell line, 32D (right), were probed with mouse cDNA.

FIGURE 3. Dominant expression of P58\textsuperscript{TFL} in human blood cells. Immunoblot analyses of human TFL in human normal WBC and leukemia cell lines. Total cell lysates of HA-tagged or nontagged TFL1 cDNA transfectants, HA-TFL1 and TFL1 (A), and immunoprecipitates of HA-tagged TFL2 cDNA transfectants, HA-TFL2, were used as controls of recombinant P58\textsuperscript{TFL} and P36\textsuperscript{TFL}, respectively. In addition to the cell lines for RNA blot analysis (Fig. 2), a mature T-cell lymphoma cell line, HUT102, was also examined. The MW of major TFL protein was 58 kDa (A). A nonspecific signal (*) was absent from immunoprecipitated samples (B).
not evident by immunoblot using whole-cell lysates. Some diffuse bands that comigrated with the recombinant P36TFL in MNC, HL60, and THP-1 immunoprecipitates are not likely to represent endogenous P36TFL because the recombinant P36TFL was tagged with hemagglutinin (HA). Thus, the major protein expressed in normal human lymphocytes was P58TFL. Moreover, aberrant expression of P58TFL was found in some human leukemic cell lines.

**TFL Inhibits DNA Synthesis and Progression to S Phase**

To clarify the biological function of TFL, a green fluorescent protein (GFP)-TFL fusion protein was expressed in an interleukin 3 (IL-3)–dependent mouse normal pro-B-cell line, Ba/F3, where the TFL mRNA expression level was less than that of mature B lymphocytes (Fig. 2B). Interestingly, although the numbers of cells expressing GFP-TFL1 or GFP-TFL2 were equivalent to the number expressing GFP alone at 4 hours after electroporation, the number of cells expressing either TFL1 or TFL2 was drastically decreased by 48 hours (Fig. 4A). We speculated that this might be due to TFL-induced growth arrest and/or cell death because the population of nontransfected Ba/F3 cells soon overwhelmed that of TFL transfectants.

To examine whether TFL could suppress DNA synthesis, we performed bromodeoxyuridine (BrdUrd) assays under G0-G1 synchronization conditions as described in Materials and Methods. As expected, the number of S-phase cells incorporating BrdUrd was decreased by introducing TFL1 or TFL2 cDNA (Fig. 4B). The number of G0-G1-phase cells among transfectants was increased proportionately. These results indicate that the G1 to S phase progression was inhibited by TFL. Inhibition of DNA synthesis by TFL was also confirmed by tritiated thymidine uptake (data not shown). The observation that growth inhibition was observed after introducing either TFL1 or TFL2 cDNAs suggests that a common protein domain between P58TFL and P36TFL might play a crucial role in cell growth control.

**TFL Suppresses Phosphorylation of Retinoblastoma Protein**

Cell cycle progression is regulated by many signaling molecules. Phosphorylation of retinoblastoma protein (Rb) plays a key role in the G1 to S phase transition (24). To determine whether TFL could inhibit Rb phosphorylation or not, we first assessed Rb phosphorylation status in Ba/F3 transfectants by intracellular flow cytometry assay (Fig. 5A). As expected, introduction of either TFL1 or TFL2 cDNA significantly restrained Rb phosphorylation compared with a control vector alone (mock). These results indicated that TFL inhibited cell cycle progression into S phase through the suppression of Rb phosphorylation. To confirm this finding in another cell line, NIH3T3 cells were transfected with the GFP-tagged TFL vectors. Rb phosphorylation was then assessed by immunofluorescence staining using a specific antibody for phospho-Rb. Cells expressing GFP-TFL1 fusion protein completely lacked Rb phosphorylation.
(Fig. 5B, middle), although Rb was phosphorylated in the mock-transfected cells (Fig. 5B, top). Similar results were found in cells expressing P36TFL as well (Fig. 5B, bottom).

**TFL Promotes Caspase-3-Dependent Apoptosis**

Apoptotic pathways are also important for the development of cancers. To examine the effect of TFL on cell apoptosis, Ba/F3 cells carrying TFL vectors were stained with Annexin V. As shown in Fig. 6A, both types of TFL increased the number of Annexin V–positive cells by 24 hours after electroporation. To confirm whether cell death was caspase-3 dependent or not, we also studied the activation of caspase-3 by flow cytometry. Ba/F3 cells carrying TFL1 as well as TFL2 vectors had significantly increased cleaved caspase-3 compared with mock transfectants (Fig. 6B). These results suggest that both P58TFL and P36TFL induced caspase-3–dependent apoptosis.

**Overexpression of TFL Alters the Carcinogenic Properties of Human Leukemia Cells**

It is interesting that the predominant lymphocytic splice form, TFL1, was not expressed in certain human leukemia cell lines as described above (Fig. 3A). To examine whether the deficiency is only correlative or causative for leukemogenesis, we tried some functional assays by introducing the TFL cDNA expression vectors into the T-cell leukemia cell line Jurkat.

Overexpression of TFL1 as well as TFL2 inhibited the growth of Jurkat cells (Fig. 7A). Moreover, TFL vectors suppressed BrdUrd incorporation and Rb phosphorylation, and it increased cleaved caspase-3–positive apoptotic cells (Fig. 7B–D). These results indicate that TFLs serve as a tumor suppressor in certain human leukemia cells.

**Differential Subcellular Localization of P58TFL and P36TFL**

We also examined the subcellular localization of P58TFL and P36TFL (Fig. 8A). P58TFL localized as discrete granules in the cytoplasm, but not at all in the nuclei, of HeLa cells. On the other hand, P36TFL localized to both cytoplasm and nuclei (but not nucleoli); nuclei were stained more intensely than the cytoplasm. The distinctive localization of P58TFL and P36TFL was confirmed in NIH3T3 and Ba/F3 transfectants (data not shown). There are some differences in the cytoplasmic-terminal sequences between P58TFL and P36TFL (Fig. 1). These differences may contribute to specific subcellular localization through as yet unidentified sequence motifs present within this region.

TFL has a single CCCH-type zinc finger motif that binds nucleic acids including RNA. mRNA processing bodies (P-bodies), where mRNA degradation or stabilization occurs, are localized to the cytoplasm as discrete granules. We predicted that P58TFL granules might colocalize with P-bodies. Thus, we cotransfected GFP-tagged P58TFL with HA-tagged P-body markers, eukaryotic translation initiation factor 2C (EIF2C2; also known as AGO2; ref. 25) or DCP1 decapping enzyme homolog A (DCP1A; ref. 26). Almost complete colocalization of P58TFL and EIF2C2 was confirmed in NIH3T3 and Ba/F3 transfectants (data not shown). There are some differences in the cytoplasmic-terminal sequences between P58TFL and P36TFL (Fig. 1). These differences may contribute to specific subcellular localization through as yet unidentified sequence motifs present within this region.

Both P-bodies and stress granules are distinct cytoplasmic aggregates involved in mRNA storage and/or degradation, but they are spatially, compositionally, and functionally linked (27, 28). It is possible that P58TFL might be also accumulating in foci near P-bodies much like stress granules. Therefore, we further examined the subcellular localization by cotransfection with a HA-tagged stress granule marker, T-cell intracellular antigen-1 (TIA-1; Fig. 8B, bottom). Most P58TFL and TIA-1 granules are distinctively localized in the cytoplasm. A few P58TFL granules were juxtaposed with TIA-1 granules, but the two granules never overlapped. Interestingly, overexpression of mouse TFL in HeLa cells promoted the fusion of endogenous TIA-1–positive stress granules with TFL granules. Some stress granules were incompletely engulfed by TFL (Supplementary Fig. S1). In contrast, other granules such as endosomes or lysosomes were not colocalized with P58TFL granules, as assessed with anti-EEA1 antibody and LysoTracker, respectively (refs. 29, 30; data not shown).
Unpublished observation.

ZC3H12C was first identified as a product of ZC3H12C and significantly increased in GFP-positive TFL1 and TFL2 transfectants versus mock. Monocyte chemoattractant protein-1–moattractant protein-1 activated monocytes (31). GFP-TFL1, and GFP-TFL2 cDNA vectors were stained with Annexin V–positive cells in GFP-positive TFL1 or TFL2 transfectants compared with that in mock transfectants (GFP alone). Results are expressed as mean ± SD of triplicate samples.

These results suggest that P58\(^{\text{TFL}}\) may be a component of the P-body, which spatially interacts with stress granules and might suppress G1 to S phase progression through posttranscriptional modification of an indispensable cell cycle regulator.

Discussion

ZC3H12D belongs to a gene family including three members, ZC3H12A, ZC3H12B, and ZC3H12C. Among them, monocyte chemoattractant protein-1–induced protein (MCPIP) was first identified as a product of ZC3H12A in monocyte chemoattractant protein-1–activated monocytes (31). ZC3H12B and ZC3H12C mRNAs were expressed in normal tissues with unique expression profiles, but their expression at the protein level has not yet been confirmed. Here, we first identified two ZC3H12D-derived splicing variants encoding possible tumor suppressors, P58\(^{\text{TFL}}\) and P36\(^{\text{TFL}}\). In contrast to the dominant expression of ZC3H12A in macrophages, ZC3H12D was expressed preferentially on normal lymphoid tissues. In particular, it was very strongly expressed on mature T and B lymphocytes rather than immature thymocytes. Whereas TFL\(^{\text{p58}}\) was undetectable in some immature hematopoietic cell lines such as Jurkat, MOLT-14, and CCRF/CEM, the mature adult T-cell leukemia cell line HUT102 expressed it intensively (Fig. 2A). MCPIP is inducible in macrophages by inflammatory stimuli, such as lipopolysaccharide, and regulates proinflammatory activation of macrophages by a negative feedback loop (32). A prototype CCCH-type zinc finger protein, tristetraprolin, encoded by the Zfp36 gene, also regulates tumor necrosis factor α in macrophages through a negative feedback loop (33). Therefore, TFL proteins might play some feedback roles in lymphocyte activation as well as maturation. It is of interest how P58\(^{\text{TFL}}\) and P36\(^{\text{TFL}}\) are regulated under T-cell receptor or Ig stimulus.

We originally identified the TFL gene ZC3H12D by cloning the breakpoint of a t(2;6)(p12;q25) translocation in a BCL-2–positive transformed follicular lymphoma (22). The 5′ region of ZC3H12D including exon 1 and exon 2 was replaced by the V\(\kappa\) and C\(\kappa\) regions of the I\(\kappa\)g gene. Originally, another 6q allele had been lost in the follicular lymphoma before the transformation. However, it remains to be elucidated whether deregulation of the gene or deletion is relevant to transformation. The growth inhibitory activities of P58\(^{\text{TFL}}\) and P36\(^{\text{TFL}}\) on a human leukemia cell line shown here support the hypothesis that loss of the biological function by translocation is implicated in transformation as a tumor suppressor. Deregulated antiapoptotic protein BCL-2, preventing cellular apoptosis in follicular lymphoma, causes massive lymphoid hyperplasia, a premalignant state (34, 35). A secondary hit at ZC3H12D in lymphocytes might result in complete loss of their normal function, facilitating a release from the growth control into tumor progression. Moreover, loss of heterozygosity of ZC3H12D was found in sporadic lung cancer, whereas normal lung expressed the mRNA. By using a human lung carcinoma cell line, Wang et al. (23) showed that a single amino acid change due to single-nucleotide polymorphism contributes to tumor progression. However, there was no significant difference in the growth inhibition between mouse pro-B-cell lines overexpressing TFL with an exchanged codon at 106, from lysine to arginine, according to the single-nucleotide polymorphism (data not shown). Whether this discrepancy is due to the cell lines used or reflects different tissue specificity is not yet clear. In addition, the four-amino-acid difference between p34 and P36\(^{\text{TFL}}\) might affect biological activity.

Suppression of Rb phosphorylation is thought to precede G\(\text{0}-\text{G}1\) arrest in P58\(^{\text{TFL}}\) and P36\(^{\text{TFL}}\) transfectants. Activated cyclin-dependent kinase phosphorylates multiple sites in Rb, and phosphorylated Rb up-regulates cell growth–related proteins (36). Microarray screening of the expression profiles of cell cycle–related genes in the transfectants revealed the down-regulation of PCNA, E2F3, and E2F4, as expected. Just as MCPIP could contribute to the suppression of tissue inflammation, TFL also might prevent from excessive lymphocyte proliferation following tissue damage, an origin of cancer development.

MCPIP is reported to induce apoptosis in monocytes as well as in cardiac myocytes (37). In addition to G\(\text{0}-\text{G}1\) arrest, caspase-3–dependent apoptosis was confirmed in Ba/F3 cells overexpressing P58\(^{\text{TFL}}\) or P36\(^{\text{TFL}}\). There are two possibilities about how apoptosis was induced in the transfectants. First, TFL may directly promote apoptosis through a different signaling pathway from that inducing G\(\text{0}-\text{G}1\) arrest. Alternatively, it may be possible that cell cycle arrest caused apoptosis in the

\(^1\) Unpublished observations.

\(^2\) Unpublished observation.
transfectants. It is meaningful to determine whether or not the apoptosis is induced in a p53-dependent manner because p53 is involved in cell cycle arrest as well as apoptosis. Apoptosis is characterized by chromatin condensation, internucleosomal degradation of the DNA, cell shrinkage, and disassembly into membrane-enclosed vesicles as a consequence of caspase-3 activation (38). Because apoptosis is generally accompanied by a reduction in cell volume, this parameter was used to discriminate between morphologically apoptotic and viable cell populations (39). Thus, we examined cell cycles as well as Rb phosphorylation by discerning such shrinkage, so-called morphologically apoptotic cells, with flow cytometry. Indeed, cleaved caspase-3-positive cells were not increased in morphologically viable cell populations at all (data not shown). In addition, the number of apoptotic cells accumulated in a time-dependent manner. These results suggest that G0-G1 arrest preceded apoptosis in Ba/F3 transfectants.

Thus far, no differences in the biological functions of P58\textsuperscript{TFL} and P36\textsuperscript{TFL} have been found. However, their subcellular distributions were distinctive. P58\textsuperscript{TFL} was shown to be colocalized with P-body–related proteins, EIF2C2 and DCP1A. Posttranscriptional mechanisms are gradually becoming better defined and are gaining attention (40). For example, EIF2C2 is a major RNA-induced silencing complex component where microRNA as well as short interference RNA is processed. RNA-induced silencing complex components play an important role for posttranscriptional pathways (25, 41). In addition to mRNA processing, sites for mRNA editing are very unique. When cellular stress triggers mRNA processing, mRNA and RNA binding proteins are gathered in cytoplasmic granules called P-bodies and stress granules (42). The tandem CCCH-type zinc finger domain originally identified in tristetraprolin binds to AU-rich elements, regulating mRNA stability (33). A similar zinc finger domain–containing protein, Roquin, was also shown to be an RNA-binding protein localized in P-bodies (43, 44). Recent surveys indicate that posttranscriptional pathways and mRNA processing pathways are indispensable to the regulation of protein expression as well as its deregulation in tumorigenesis. With this in mind, P58\textsuperscript{TFL} might bind to certain RNA AU-rich elements and be involved in posttranscriptional modification. More comprehensive assays will be required to identify target molecules of P58\textsuperscript{TFL} and define its role as an RNA binding protein.

In contrast, MCPIP is thought to work as a transcription factor (45). Similarly, P36\textsuperscript{TFL} contains the same zinc finger domain and might be a transcriptional factor because of its unique localization in the nucleus but not nucleoli. The identification of molecular targets of P58\textsuperscript{TFL} and P36\textsuperscript{TFL} would help address the question of how these proteins control cell cycle and apoptosis.

The data presented here show that P58\textsuperscript{TFL} and P36\textsuperscript{TFL} regulate cell growth likely by suppressing Rb phosphorylation. Although future studies are needed to ascertain whether the deregulation P58\textsuperscript{TFL} and/or P36\textsuperscript{TFL} is actually involved

![Figure 7](https://example.com/figure7.png)

**FIGURE 7.** Overexpression of TFL alters the leukemogenic properties of Jurkat cells. A. Human T-cell leukemia Jurkat cells (5 × 10\textsuperscript{6}) were nucleofected with vectors containing GFP-tagged mock, TFL1, or TFL2 cDNA vectors. GFP-positive cells were analyzed by flow cytometry at 6, 16, 24, and 48 h after electroporation. Living cell numbers were counted by trypan blue method. Representative cell growth curves of transfectants. *, \(P<0.01\), GFP-positive cells in TFL1 and TFL2 transfectants compared with mock transfectants. Points, mean of triplicate samples; bars, SD. B. Jurkat cells overexpressing TFLs were cultured for 24 and 48 h to assess for BrdUrd incorporations. Representative three independent BrdUrd assays using mock, TFL1, and TFL2 cDNA transfectants. The bar graph shows percentage of GFP-positive cells in S phase. *, \(P<0.01\), BrdUrd-positive cells in TFL1 and TFL2 transfectants compared with mock transfectants. Columns, mean of triplicate samples; bars, SD. C. Phosphorylation levels of Rb in Jurkat cells overexpressing TFL1 or TFL2 were analyzed by intracellular flow cytometry using Cy5-conjugated phospho-Rb–specific antibody. *, \(P<0.01\), phospho-Rb–positive cells in TFL1 and TFL2 transfectants compared with mock transfectants. Columns, mean of triplicate samples; bars, SD. D. Increased apoptosis was shown in Jurkat cells overexpressing TFLs. *, \(P<0.01\), percentage of active caspase-3–positive cells in GFP-positive TFL1 or TFL2 transfectants compared with mock transfectants. Columns, mean of triplicate samples; bars, SD.
in tumor progression in vivo, it is of interest to study their potential utility as diagnostic as well as potential therapeutic targets in various malignancies.

**Materials and Methods**

**Human cDNA Cloning**

RNAs were extracted from human lymph nodes with Trizol (Invitrogen). After DNase I digestion, cDNA was prepared using PrimeScript RTase (Takara, Japan). PCR was done with high-fidelity PrimeSTAR HS DNA Polymerase (Takara) using several primer sets designed using the NCBI database. Sequencing of PCR products was done using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). PCR using just one primer set showed several bands, and sequence analyses showed at least two patterns of splice variants. To clone the TFL1 and TFL2 human cDNAs into expression vectors, the following primer sets were used: a common forward primer, 5′-ATGGAGCACCCCAGCAAGAT-3′, and reverse primers for TFL1, 5′-TTAGGGCTTGCCCAGGGGCGCCC-3′, and TFL2, 5′-CTAGGGCGGTGTTCGCCCCGCGG-3′. To confirm the 3′UTR, we also screened a cDNA library from human peripheral blood (Clontech).

**FIGURE 8.** Distinct subcellular localization of P58TFL and P36TFL. A. Each expression vector of GFP alone or GFP-fused P58TFL or P36TFL was transfected into HeLa cells. Cell nuclei are stained with 4′,6-diamidino-2-phenylindole (DAPI). B. HA-tagged EIF2C2, DCP1A, or TIA-1 vector was cotransfected with a GFP-fused P58TFL vector into HeLa cells. HA-tagged P-body and stress granule markers were visualized with Cy5-conjugated antibody.
Cells

Ba/F3 and 32D mouse cell lines were maintained in RPMI 1640 containing 10% FCS (JRH Biosciences) and 15% WEHI-conditioned medium (46). Leukemia cell lines, HL-60, THP-1, Jurkat, MOLT-14, CCRF-CEM, HUT102, Daudi, and NALM-6, were maintained in suspension culture using RPMI 1640 containing 10% FCS (47). NIH3T3 and HeLa cells were maintained in DMEM containing 10% calf bovine serum.

Human and mouse T and B lymphocytes (MNC) were isolated by Dynabeads using specific monoclonal antibodies (Dynabeads BioTech). Mononuclear and polymorphonuclear cells were isolated by Lympholyte-H (Cedarlane) and Histopaque-1119 (Sigma).

RNA Blot Analyses

RNA blots were hybridized with 32P-labeled human and mouse TFL cDNA probes. A 963-bp human TFL probe, which includes the complete ORF of TFL2, was amplified using a forward primer, 5'-ATGGAGCCACCCAGCAAGTGAATTCC-3', and a reverse primer, 5'-CTACCCACATAGAAGCAATGTCG-3'. A 600-bp mouse cDNA probe, which includes the homologous region of human TFL2 cDNA ORF, was amplified from mouse spleen lymphocyte RNA using a forward primer, 5'-ATGAGC-CATGGAATACAGACGCT-3', and a reverse primer, 5'-ACCCGACCGAGCGGTCTTGCA-3'.

Antisera

Antihuman TFL polyclonal antibody was generated by immunization of rabbits with glutathione S-transferase (GST) fusion protein containing full-length P36TFL (Operon). A GST-P36TFL expression vector was constructed using the pGEX-2TL vector (Amersham Biosciences). Crude rabbit serum was purified with an HA-tagged vector described above using the pQBI25GFP vector. Each cloned cDNA including its complete ORF was introduced using the NheI site of the vector. HA-tagged human TIA-1 antibody (Takara, Japan) before mounting. For detection of endogenous human TIA-1, we used anti-HA antibody (Covance) overnight at 4°C followed by incubation with antimouse secondary antibody conjugated with Cy5 (Jackson ImmunoReserch).

For flow cytometric analyses of phospho-Rb, cells were fixed with 4% formaldehyde and permeabilized with 90% methanol, and then incubated with rabbit anti-mouse serine 807/811 phosphorylated Rb (Cell Signaling Technology) followed by incubation with antirabbit secondary antibody conjugated with Cy5 (Jackson ImmunoReserch). Annexin V-Cy5 (Becton Dickinson), biotinylated anti–active caspase-3 (Becton Dickinson), and streptavidin-allophycocyanin (e-Biosciences) were used to evaluate cell apoptosis.

Immunofluorescence Staining

Cells were grown on eight-chamber slides (Nunc). After transfection with TFL vectors, cells were fixed with 4% formaldehyde and permeabilized with 0.3% Triton X-100. After blocking procedures, cells were incubated with mouse anti-HA antibody (Covance) overnight at 4°C followed by incubation with antimouse secondary antibody conjugated with Cy5 (Jackson ImmunoReserch) before mounting. For detection of endogenous human TIA-1, we used anti–TIA-1 antibody (Santa Cruz) and secondary antibody conjugated with Alexa488 (Molecular Probes). Fluorescence was analyzed by confocal microscopy (510META, Carl Zeiss).

Statistical Analysis

Student’s t test was used for comparisons of numerical values in cell growth and apoptosis assays.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Donald P. Bottaro for critical review of the manuscript, and Chie Fukui for technical assistance.

References


Inhibition of G1 to S Phase Progression by a Novel Zinc Finger Protein P58 TFL at P-bodies

Kentaro Minagawa, Yoshio Katayama, Shinichiro Nishikawa, et al.


Updated version Access the most recent version of this article at: doi:10.1158/1541-7786.MCR-08-0511

Supplementary Material Access the most recent supplemental material at: http://mcr.aacrjournals.org/content/suppl/2009/06/07/1541-7786.MCR-08-0511.DC1

Cited articles This article cites 46 articles, 18 of which you can access for free at: http://mcr.aacrjournals.org/content/7/6/880.full.html#ref-list-1

Citing articles This article has been cited by 5 HighWire-hosted articles. Access the articles at: http://mcr.aacrjournals.org/content/7/6/880.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.